Molecular & Cellular Proteomics · 2010 · 80 citations · 25 references
Life SciencesBiochemistryMolecular BiologyCancer ScreeningMolecular DiagnosticsProteomicsClinical ProteomicsProtein CharacterizationProtein IdentificationProtein MicroarraysProteomic BiomarkersProteomic ProfilingAntigen ArraysClinical Proteomics AssaysProtein Biomarker ProfilingProtein Biomarker ScreeningProtein Biomarker ValidationProtein BiomarkersProteome-wide ProfilingProteomic Biomarker Validation
There is a need for high throughput methods for screening patient samples in the quest for potential biomarkers for diagnostics and patient care. Here, we used a combination of undirected target selection, antibody suspension bead arrays, and heat-induced epitope retrieval to allow for protein profiling of human plasma in a novel and systematic manner. Several antibodies were found to reveal altered protein profiles upon epitope retrieval at elevated temperatures with limits of detection improving into lower ng/ml ranges. In a study based on prostate cancer patients, several proteins with differential profiles were discovered and subsequently validated in an independent cohort. For one of the potential biomarkers, the human carnosine dipeptidase 1 protein (CNDP1), the differences were determined to be related to the glycosylation status of the targeted protein. The study shows a path of pursuit for large scale screening of biobank repositories in a flexible and proteome-wide fashion by utilizing heat-induced epitope retrieval and using an antibody suspension bead array format. There is a need for high throughput methods for screening patient samples in the quest for potential biomarkers for diagnostics and patient care. Here, we used a combination of undirected target selection, antibody suspension bead arrays, and heat-induced epitope retrieval to allow for protein profiling of human plasma in a novel and systematic manner. Several antibodies were found to reveal altered protein profiles upon epitope retrieval at elevated temperatures with limits of detection improving into lower ng/ml ranges. In a study based on prostate cancer patients, several proteins with differential profiles were discovered and subsequently validated in an independent cohort. For one of the potential biomarkers, the human carnosine dipeptidase 1 protein (CNDP1), the differences were determined to be related to the glycosylation status of the targeted protein. The study shows a path of pursuit for large scale screening of biobank repositories in a flexible and proteome-wide fashion by utilizing heat-induced epitope retrieval and using an antibody suspension bead array format. There is a great need for protein biomarkers for early diagnosis of disease as well as for prognostic markers in which the outcome of a particular disease or treatment can be predicted (1Hanash S. Disease proteomics.Nature. 2003; 422: 226-232Crossref PubMed Scopus (874) Google Scholar). In particular, biomarkers that make it possible to monitor the progress of treatment or the reoccurrence of a particular disease are of great clinical value. However, there are still few protein biomarkers in clinical practice today, and despite many biomarker discovery efforts by many laboratories using many different approaches, a limited number have been introduced into the clinical routine during the last 10 years (2Ludwig J.A. Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection.Nat. Rev. Cancer. 2005; 5: 845-856Crossref PubMed Scopus (1346) Google Scholar). The complexity of serum or plasma proteomes with their broad dynamic range of protein concentrations and the lack of high throughput methods with high sensitivity have hampered such discovery and validation efforts. The most common approach for protein biomarker discovery today is the use of proteomics methods in which samples from case-control groups are compared using biochemical and biophysical methods, most notably with mass spectrometry (3Hanash S.M. Pitteri S.J. Faca V.M. Mining the plasma proteome for cancer biomarkers.Nature. 2008; 452: 571-579Crossref PubMed Scopus (691) Google Scholar). The introduction of more and more sophisticated instrumentation has increased the sensitivity and throughput of mass spectrometry during the last years (4Cox J. Mann M. Is proteomics the new genomics?.Cell. 2007; 130: 395-398Abstract Full Text Full Text PDF PubMed Scopus (351) Google Scholar). One of the advantages with mass spectrometry is that the method also allows for the detection of differences in protein modifications, such as glycosylation or phosphorylation, which have been found useful for some applications (5Wu S.L. Kim J. Bandle R.W. Liotta L. Petricoin E. Karger B.L. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA).Mol. Cell. Proteomics. 2006; 5: 1610-1627Abstract Full Text Full Text PDF PubMed Scopus (83) Google Scholar). Although many potential biomarkers have been discovered using mass spectrometry, the approach is yet limited to the analysis of a relatively small number of patient samples. The alternative approach for biomarker discovery is to use affinity probes, usually antibodies but also other reagents, such as aptamers (6Bock L.C. Griffin L.C. Latham J.A. Vermaas E.H. Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin.Nature. 1992; 355: 564-566Crossref PubMed Scopus (2135) Google Scholar) or Affibody molecules (7Nord K. Gunneriusson E. Ringdahl J. Ståhl S. Uhlén M. Nygren P.A. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain.Nat. Biotechnol. 1997; 15: 772-777Crossref PubMed Scopus (532) Google Scholar). The advantage of such probe-based methods is the possibility to analyze many samples in parallel, and many assays based on antibodies, such as ELISA, are very sensitive in the sub-ng/ml range. In particular, sandwich immunoassays in which two separate antibodies are used to increase the sensitivity and selectivity allow proteins to be assayed down to pg/ml (8Kingsmore S.F. Multiplexed protein measurement: technologies and applications of protein and antibody arrays.Nat. Rev. Drug Discov. 2006; 5: 310-320Crossref PubMed Scopus (604) Google Scholar). Recently, new assays based on amplification methods have been described, such as the proximity ligation method (9Fredriksson S. Gullberg M. Jarvius J. Olsson C. Pietras K. Gústafsdóttir S.M. Ostman A. Landegren U. Protein detection using proximity-dependent DNA ligation assays.Nat. Biotechnol. 2002; 20: 473-477Crossref PubMed Scopus (1077) Google Scholar), and these have the potential to score protein on a single molecule level. However, the lack of validated antibodies to most human proteins (10Björling E. Uhlén M. Antibodypedia, a portal for sharing antibody and antigen validation data.Mol. Cell. Proteomics. 2008; 7: 2028-2037Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar) makes it impossible to use antibody-based protocols for a majority of the potential protein targets, and this is even more difficult for assays based on paired antibodies that require two distinct antibodies with separate and non-overlapping epitopes. Because of this limitation, current studies are directed by candidate target lists reported in the literature (11Shafer M.W. Mangold L. Partin A.W. Haab B.B. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.Prostate. 2007; 67: 255-267Crossref PubMed Scopus (65) Google Scholar) or in associated gene expression studies (12Sanchez-Carbayo M. Socci N.D. Lozano J.J. Haab B.B. Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays.Am. J. Pathol. 2006; 168: 93-103Abstract Full Text Full Text PDF PubMed Scopus (154) Google Scholar) or built on collections of in-house binder libraries (13Carlsson A. Wingren C. Ingvarsson J. Ellmark P. Baldertorp B. Fernö M. Olsson H. Borrebaeck C.A. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.Eur. J. Cancer. 2008; 44: 472-480Abstract Full Text Full Text PDF PubMed Scopus (94) Google Scholar). Recently, new efforts have been described for the generation of antibodies on a whole-proteome level (14Uhlén M. Björling E. Agaton C. Szigyarto C.A. Amini B. Andersen E. Andersson A.C. Angelidou P. Asplund A. Asplund C. Berglund L. Bergström K. Brumer H. Cerjan D. Ekström M. Elobeid A. Eriksson C. Fagerberg L. Falk R. Fall J. Forsberg M. Björklund M.G. Gumbel K. Halimi A. Hallin I. Hamsten C. Hansson M. Hedhammar M. Hercules G. Kampf C. Larsson K. Lindskog M. Lodewyckx W. Lund J. Lundeberg J. Magnusson K. Malm E. Nilsson P. Odling J. Oksvold P. Olsson I. Oster E. Ottosson J. Paavilainen L. Persson A. Rimini R. Rockberg J. Runeson M. Sivertsson A. Sköllermo A. Steen J. Stenvall M. Sterky F. Strömberg S. Sundberg M. Tegel H. Tourle S. Wahlund E. Waldén A. Wan J. Wernérus H. Westberg J. Wester K. Wrethagen U. Xu L.L. Hober S. Pontén F. A human protein atlas for normal and cancer tissues based on antibody proteomics.Mol. Cell. Proteomics. 2005; 4: 1920-1932Abstract Full Text Full Text PDF PubMed Scopus (1048) Google Scholar). Version 6 of the Human Protein Atlas contains validated antibodies toward proteins from 8,400 human genes, corresponding to 42% of the in antibodies in the Human Protein Atlas are and a of more antibody from the and Several other such as the Borrebaeck C.A. D. C. A. S. J. R. D. L. H. M. B. E. S. Landegren U. S. J. S. Nygren P.A. S. A. B. M. P. A. A. M. M. Uhlén M. a of affinity for analysis of the human 2007; 4: PubMed Scopus Google Scholar), the M. S. M. A to affinity to human 2008; 5: PubMed Scopus Google Scholar), and the affinity B.B. H. J. M. A to proteins and of for the cancer a Cell. Proteomics. 2006; 5: Full Text Full Text PDF PubMed Scopus Google Scholar), have been with the to affinity toward human protein The of these efforts is to have antibodies to a protein from of the by M. the human proteome using Cell. Proteomics. 2007; Full Text Full Text PDF PubMed Google Scholar), and this the need to high throughput methods for protein profiling to this of antibodies to allow high throughput biomarker have that antibodies in suspension bead can be used for profiling proteins in serum and plasma M. Rimini R. Uhlén M. Nilsson P. Antibody suspension bead serum 2008; 7: PubMed Scopus Google Scholar). we found that the to proteins such as of the by most be at elevated temperatures and for antibody In particular, this is to be the for antibodies on the protein Here, we the of antibodies different epitope retrieval protocols at different and we a method for analysis of plasma or serum using plasma from with elevated used of of Protein receptor dipeptidase 1 protein as an A method for analysis of large of biobank samples is antigen of detection of Human Protein Atlas receptor 1 carnosine dipeptidase 1 protein protein for antigen selection, and of by affinity to antibodies, and their with and antigen were as described P. Paavilainen L. Larsson K. Odling J. Sundberg M. Andersson A.C. Kampf C. Persson A. Szigyarto C. Ottosson J. Björling E. Hober S. Wernérus H. Wester K. Pontén F. M. a human proteome generation of antibodies for 2005; 5: PubMed Scopus Google C. J. I. L. Hansson M. Asplund A. E. S. I. Wester K. D. C. Lundeberg J. Ståhl S. Pontén F. Uhlén M. proteomics for systematic protein profiling of gene in human Cell. Proteomics. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). protein used for were with a protein and a target protein of In antibodies were selected for this were for from and which in recombinant an protein and antibodies factor and from were with recombinant and by plasma samples from were and been determined during clinical routine The samples were based on these clinical and used during For a case-control study of prostate cancer in The study has been described in S.L. J. F. S. P. G. K. W. D. B.L. Xu J. H. of with prostate J. 2008; PubMed Scopus Google Scholar). and the at and this plasma samples were used and as one of the or and or were as and or and samples were from prostate were to to the and as described M. Rimini R. Uhlén M. Nilsson P. Antibody suspension bead serum 2008; 7: PubMed Scopus Google Scholar). The for antibody determined antibody and a bead as described J. Sundberg M. Uhlén M. Nilsson P. of in assays for antibody proteomics.Mol. Cell. Proteomics. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar). Serum and plasma samples were and in with studies M. Rimini R. Uhlén M. Nilsson P. Antibody suspension bead serum 2008; 7: PubMed Scopus Google R. Sundberg M. R. D. M. Uhlén M. Nilsson P. of serum protein profiles by a antibody array Proteomics. PubMed Scopus Google Scholar) with samples were at for 10 at and into a The were at and of to of with a of at to an by a at in a The by the of a of and for at to a at samples were subsequently and in an of and in in with The samples were in a for at or for at or at to of bead in a and on a at an were in with of on a by 10 with of a in were with 1 of and of in and for were with and in of samples were of serum and by the use of Affibody molecules to as described C. A. Hober S. Affibody molecule of and using different for of PubMed Scopus Google Scholar). were in and the to by The by with and were in in for were at concentrations at in the were in for and detection using antibody and a The a and were using an bead were and were as analysis using R. R. A for Analysis and 5: Scholar), and the were by as described U. G. F. Uhlén M. Nilsson P. protein profiling of serum and plasma using an antibody suspension bead array PubMed Scopus Google Scholar). and a of detection determined a to reveal the antigen at a which determined in a that been with In to the of determined at were based on and For and samples were and based on from a S. and J. M. The of samples used are in For were for a analysis using a of the and methods for differential expression in PubMed Scopus Google Scholar), and were using a to a for and for For profiles were with a to and were The profiles and clinical using The for high throughput systematic protein profiling using antibody suspension bead is in are to the to and to an antibody bead array in samples are and with The samples are in and with the bead A detection molecule is introduced after proteins are by The interaction antibody and target protein is reported the of the bead and to profiles samples. of are and the of protein target is based on the of been M. Rimini R. Uhlén M. Nilsson P. Antibody suspension bead serum 2008; 7: PubMed Scopus Google Scholar) that molecules have to be from the samples plasma is to the In the require of serum and can be using The advantage of using this based on is that of to several different assays in is possible bead is and there is in the to the of with many of different antibodies in the a of antibodies based on and independent of the of more antibodies validated the of the Human Protein Atlas L. Björling E. Oksvold P. Fagerberg L. Asplund A. Szigyarto C.A. Persson A. Ottosson J. Wernérus H. Nilsson P. E. Sivertsson A. S. Wester K. Kampf C. Hober S. Pontén F. Uhlén M. A human protein atlas for expression profiles based on Cell. Proteomics. 2008; 7: Full Text Full Text PDF PubMed Scopus Google Scholar) The and using antigen are of protein which are in a of and of the antibodies bind to the antigen L. Björling E. Oksvold P. Fagerberg L. Asplund A. Szigyarto C.A. Persson A. Ottosson J. Wernérus H. Nilsson P. E. Sivertsson A. S. Wester K. Kampf C. Hober S. Pontén F. Uhlén M. A human protein atlas for expression profiles based on Cell. Proteomics. 2008; 7: Full Text Full Text PDF PubMed Scopus Google Scholar). of these antibodies have a of more after affinity from the Antibody with a were to lower of proteins to be the of the A based on antibodies that a single at the protein with a single plasma and the the number of antibodies with the bead antibodies from that were selected for the study based on their on the protein arrays, their in and their these antibodies were on to a bead array to the of antibody proteins from different such as proteins plasma proteins proteins proteins with a and The of treatment on antigen retrieval with different temperatures samples at temperatures the plasma to to and of many proteins in the plasma Several in the of the M. Rimini R. Uhlén M. Nilsson P. Antibody suspension bead serum 2008; 7: PubMed Scopus Google Scholar) were and a of and selected for the epitope retrieval and for One plasma in and using the antibodies in the described with treatment from to For determined at different were compared with the at and the number of at and treatment and the for the antibodies were to protein profiles in to A of the in are in at and a and in of the protein profiles and from were but to of the temperatures described The for treatment at were to a of the that protein profiles are and that epitope can be altered and for biomarker discovery is the sensitivity of the the of on of antibodies in and were used to analyze plasma at and in The are in with the that the samples were at as compared with were for temperatures for the antibody a down to ng/ml with increased of and ng/ml were The determined with the antibody altered by a factor of down to 1 ng/ml after treatment to with of and ng/ml this analysis of plasma with recombinant a in and in were the the and the of detection to be with the treatment to the of the antibodies to the target protein in an an of heat-induced antigen retrieval in The of treatment of plasma samples with the of proteins associated to disease or disease samples were from during in the routine and into different groups of in based on and The of prostate cancer high in A and for the two and in the The of determined in the plasma samples using The samples in the and for the of The using the methods at and were subsequently compared with the using a routine method used in the The determined in samples with were found to be and to with and the to from for to for using these antibodies to the different patient differences of A and the patient groups were a treatment at differences be for compared with groups and in increase in to separate groups with an elevated retrieval the that the detection of recombinant to be upon The plasma samples from this patient were subsequently in a study using the antibodies selected a few patient can be from samples at epitope retrieval temperatures of and by the in different were for treatment that the potential to new in the of patient and disease differences different groups and for the a to and a can be found in The that proteins with differential protein profiles were at retrieval A number of potential biomarker were in this discovery and were found to be different using one of the retrieval The protein profiles for carnosine dipeptidase 1 protein (CNDP1), were to be different at and antigen retrieval treatment patient A compared with the other the of for the in the different patient are in for of the protein the by the of protein profiles from two independent which were that antibodies and samples at The of profiles determined by and for antibodies that of in independent The by receptor 1 and For of the discovered potential biomarkers, a validation of the by patient samples from were of and and and antibodies were to the of in The analysis of which found using the retrieval a very the two groups with a in the in plasma samples from in protein for plasma from A For discovered at the and retrieval an For this and serum have been P. H. W. Serum in plasma and validation of a method and in 2003; PubMed Scopus Google Scholar), and it is predicted to be at two and Although at to the to be in for samples. A at the predicted of of the and of this were the two The that the antibody to this of the dipeptidase using the suspension bead are using the The from that the of the patient the in a manner. For the protein protein a in the are but the the two groups is of the samples were from B. In the analysis the majority of from the high throughput suspension bead array and also of one of the protein The markers by the in were validated to in to a to independent and different patient of prostate cancer from a separate clinical plasma samples from with two of were with samples from a samples from of the groups were assayed with a For these the protein profiles and into and a that many markers discovered as different in the discovery were in the validation cohort. However, profiles determined for were to be lower in as compared with as in to antibody for which protein profiles were associated with more for and were found to analysis differences in profiles that were in with the and based on at in samples of more Here, we that antibody-based profiling using heat-induced antigen retrieval in combination with a suspension bead array approach allows for sensitive protein profiling in human plasma in a systematic manner. A suspension bead array used in this but it is also possible to use other array such as with antibodies R. Sundberg M. R. D. M. Uhlén M. Nilsson P. of serum protein profiles by a antibody array Proteomics. PubMed Scopus Google Scholar) or with antibodies to D. S.J. in approach to PubMed Scopus Google Scholar). However, the suspension bead array a need for plasma or serum with a flexible in which antibodies can be by different of The method described with and antibodies, and there are other affinity reagents, such as after to the that of plasma or serum from an patient is to assays for the analysis of target makes this very for screening biobank of is to allow for analysis of of protein using For the we have a systematic study of antigen retrieval for antibody-based plasma The of of or used for antigen retrieval in assays F. E. F. of the in antigen retrieval for PubMed Scopus Google Scholar), makes the to into to the heat-induced antigen to a combination of many such as the or and of the the of the protein target at different However, as many protein from antigen retrieval at or For the the also with the treatment with to detection and the possibility to differences for 1 and also that proteins with concentrations 1 ng/ml to using the combination of heat-induced epitope retrieval and also be to the described method on novel such as single molecule L. L. serum proteins at Biotechnol. PubMed Scopus Google Scholar). the it also that the of the different antibodies increase for samples for clinical samples with to this that in these is to The dynamic range of protein concentrations found in plasma and serum is very at of (3Hanash S.M. Pitteri S.J. Faca V.M. Mining the plasma proteome for cancer biomarkers.Nature. 2008; 452: 571-579Crossref PubMed Scopus (691) Google Scholar). one use a sandwich to allow sensitive assays in the of more serum but we that a single antibody protein target can be to proteins with ng/ml have other recombinant human proteins and antibodies, and the limits of detection based on these assays were also found to be in the lower ng/ml range. M. and H. be possible to increase the sensitivity of the method even by the most serum or plasma the described is of and the bead and for of for or to down the number of for antibody can be to analyze samples as described R. Sundberg M. R. D. M. Uhlén M. Nilsson P. of serum protein profiles by a antibody array Proteomics. PubMed Scopus Google Scholar). analysis used for the to several the discovery of a potential biomarker of the protein the to be the compared is of that validation of the potential biomarkers be in independent and methods are to on the glycosylation status of the protein. In the it be to the discovered proteins are also in samples of yet with prostate candidate from such discovery can be used to clinical a validation of a potential disease marker is of the use of antibodies a validation the using the suspension bead array also can be used in this The antibody-based profiling described is an to biomarker discovery using other proteomics spectrometry on the of protein probes, and this also allows and protein modifications to be However, biomarkers found by mass spectrometry usually be validated with antibodies to allow validation in large patient and to a for the clinical However, it is of possible to antibody-based protein profiling and mass spectrometry by using by analysis of the by mass be an in the for biomarkers and allow for very sensitive of proteins and The throughput with the instrumentation used in this study two of to analyze of samples with antibodies or that from assays can be and in a a advantage in of throughput compared with Recently, an for increased high throughput has been and with this we have been to antibodies in one single well to patient samples. M. that more assays can be in a single the possibility for very large scale of biobank samples are with of In this it is to that validated antibodies to proteins corresponding to of the human and more antibodies are to the of antibodies toward human proteins (10Björling E. Uhlén M. Antibodypedia, a portal for sharing antibody and antigen validation data.Mol. Cell. Proteomics. 2008; 7: 2028-2037Abstract Full Text Full Text PDF PubMed Scopus (101) Google Scholar). In we a method for systematic analysis of biobank samples using antibody-based protein that plasma to the analysis in many for increased The based on bead the possibility for using and a proteome-wide analysis of proteins in serum and biomarker discovery and validation in an undirected and high throughput manner. Fagerberg for with antibody into protein for with antibody and for The of the Human Protein Atlas in and and in are for efforts. with
25
Selection of single-stranded DNA molecules that bind and inhibit human thrombin
Louis C. Bock, Linda C. Griffin, John Latham et al. · Nature · 1992 · 2.5K citations
A Human Protein Atlas for Normal and Cancer Tissues Based on Antibody Proteomics
Mathias Uhlén, Erik Björling, Charlotta Agaton et al. · Molecular & Cellular Proteomics · 2005 · 1.6K citations · Full text